Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARLYS: MST-0312 in Solid Malignancies
NCT07610941Phase 1Recruiting
- Sponsor
- Mestag Therapeutics
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of MST-0312 (Mestag Therapeutics) in non-small cell lung cancer (NSCLC), melanoma, bladder cancer and 2 more (5 arms), sponsored by Mestag Therapeutics. Primary endpoints: Dose-limiting Toxicities at 3 weeks and Adverse Events at 24 months. Started Apr 2026; status: recruiting.
02
Drugs
MST-0312 (Mestag Therapeutics)
03
Conditions
non-small cell lung cancer (NSCLC)melanomabladder cancercolorectal cancer (CRC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07610941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07610941.